Literature DB >> 32462882

Emerging strategies to target cancer metabolism and improve radiation therapy outcomes.

Martin Kery, Ioanna Papandreou1.   

Abstract

Cancer-specific metabolic changes support the anabolic needs of the rapidly growing tumor, maintain a favorable redox balance, and help cells adapt to microenvironmental stresses like hypoxia and nutrient deprivation. Radiation is extensively applied in a large number of cancer treatment protocols but despite its curative potential, radiation resistance and treatment failures pose a serious problem. Metabolic control of DNA integrity and genomic stability can occur through multiple processes, encompassing cell cycle regulation, nucleotide synthesis, epigenetic regulation of gene activity, and antioxidant defenses. Given the important role of metabolic pathways in oxidative damage responses, it is necessary to assess the potential for tumor-specific radiosensitization by novel metabolism-targeted therapies. Additionally, there are opportunities to identify molecular and functional biomarkers of vulnerabilities to combination treatments, which could then inform clinical decisions. Here, we present a curated list of metabolic pathways in the context of ionizing radiation responses. Glutamine metabolism influences DNA damage responses by mechanisms such as synthesis of nucleotides for DNA repair or of glutathione for ROS detoxification. Repurposed oxygen consumption inhibitors have shown promising radiosensitizing activity against murine model tumors and are now in clinical trials. Production of 2-hydroxy glutarate by isocitrate dehydrogenase1/2 neomorphic oncogenic mutants interferes with the function of α-ketoglutarate-dependent enzymes and modulates Ataxia Telangiectasia Mutated (ATM) signaling and glutathione pools. Radiation-induced oxidative damage to membrane phospholipids promotes ferroptotic cell loss and cooperates with immunotherapies to improve tumor control. In summary, there are opportunities to enhance the efficacy of radiotherapy by exploiting cell-inherent vulnerabilities and dynamic microenvironmental components of the tumor.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32462882      PMCID: PMC8519637          DOI: 10.1259/bjr.20200067

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.629


  90 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Regulation of ferroptotic cancer cell death by GPX4.

Authors:  Wan Seok Yang; Rohitha SriRamaratnam; Matthew E Welsch; Kenichi Shimada; Rachid Skouta; Vasanthi S Viswanathan; Jaime H Cheah; Paul A Clemons; Alykhan F Shamji; Clary B Clish; Lewis M Brown; Albert W Girotti; Virginia W Cornish; Stuart L Schreiber; Brent R Stockwell
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

3.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Authors:  Yan Shu; Steven A Sheardown; Chaline Brown; Ryan P Owen; Shuzhong Zhang; Richard A Castro; Alexandra G Ianculescu; Lin Yue; Joan C Lo; Esteban G Burchard; Claire M Brett; Kathleen M Giacomini
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 4.  Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.

Authors:  Owen Clark; Katharine Yen; Ingo K Mellinghoff
Journal:  Clin Cancer Res       Date:  2016-01-27       Impact factor: 12.531

5.  Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism.

Authors:  Martin Benej; Xiangqian Hong; Sandip Vibhute; Sabina Scott; Jinghai Wu; Edward Graves; Quynh-Thu Le; Albert C Koong; Amato J Giaccia; Bing Yu; Ching-Shih Chen; Ioanna Papandreou; Nicholas C Denko
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-10       Impact factor: 11.205

Review 6.  Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.

Authors:  Ourania Romanidou; Vassiliki Kotoula; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 3.395

Review 7.  Antimalarial pharmacology and therapeutics of atovaquone.

Authors:  Gemma L Nixon; Darren M Moss; Alison E Shone; David G Lalloo; Nicholas Fisher; Paul M O'Neill; Stephen A Ward; Giancarlo A Biagini
Journal:  J Antimicrob Chemother       Date:  2013-01-04       Impact factor: 5.790

8.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Authors:  Luika A Timmerman; Thomas Holton; Mariia Yuneva; Raymond J Louie; Mercè Padró; Anneleen Daemen; Min Hu; Denise A Chan; Stephen P Ethier; Laura J van 't Veer; Kornelia Polyak; Frank McCormick; Joe W Gray
Journal:  Cancer Cell       Date:  2013-10-03       Impact factor: 31.743

9.  Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers.

Authors:  Ling F Ye; Kunal R Chaudhary; Fereshteh Zandkarimi; Andrew D Harken; Connor J Kinslow; Pavan S Upadhyayula; Athanassios Dovas; Dominique M Higgins; Hui Tan; Yan Zhang; Manuela Buonanno; Tony J C Wang; Tom K Hei; Jeffrey N Bruce; Peter D Canoll; Simon K Cheng; Brent R Stockwell
Journal:  ACS Chem Biol       Date:  2020-01-14       Impact factor: 4.634

10.  The histological structure of some human lung cancers and the possible implications for radiotherapy.

Authors:  R H THOMLINSON; L H GRAY
Journal:  Br J Cancer       Date:  1955-12       Impact factor: 7.640

View more
  4 in total

Review 1.  Targeting the methionine addiction of cancer.

Authors:  Joni C Sedillo; Vincent L Cryns
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

2.  Circ_0000003 regulates glutamine metabolism and tumor progression of tongue squamous cell carcinoma via the miR‑330‑3p/GLS axis.

Authors:  Cuijuan Qian; Shihang Chen; Sen Li; Yichao Wang; Jun Yao
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

Review 3.  Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development.

Authors:  Reem Aljanabi; Lina Alsous; Dima A Sabbah; Halise Inci Gul; Mustafa Gul; Sanaa K Bardaweel
Journal:  Molecules       Date:  2021-10-04       Impact factor: 4.411

Review 4.  Interfering with Tumor Hypoxia for Radiotherapy Optimization.

Authors:  Irma Telarovic; Roland H Wenger; Martin Pruschy
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.